Compare GSK plc (GSK) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Gartner Inc — how do they compare? GSK plc trades at $52.7 (market cap $101.34B), while Gartner Inc trades at $138.75 (market cap $8.96B). The key difference: GSK plc is far larger — about 11.3× Gartner Inc's market cap, and GSK plc pays a 3.49% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| GSK | IT | |
|---|---|---|
Market Cap | $101.34B | $8.96B |
Sector | Health | Technology |
52-Week High | $61.18 | $363.58 |
52-Week Low | $36.20 | $125.68 |
Enterprise Value | $121.95B | $10.55B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Gartner (IT) trades at $136.24, up 2.46% today, with a bearish technical signal but strong fundamentals including a 13.22 P/E ratio and consistent earnings beats. Revenue grew to $6.5B in 2025, though net income fell to $729M. Recent news highlights ongoing legal investigations and the company's influential role in tech research, with multiple firms named in Gartner reports.
The stock presents a mixed outlook: valuation metrics are attractive and analyst consensus targets $157.60, but technical weakness and legal overhangs pose near-term risks. Earnings momentum remains a key catalyst, though investor sentiment is cautious amid competition and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
